top of page

Free Biopharma Daily Stock Updates - 08/24/21

$XBI $127.75 +/-0.0%


Covid Updates

$SRNE +1.9% Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University. source

$TNXP +2.3% Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC). source

Pipeline Updates

$MOR +3.9% Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma source

$RNA -1.3% European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001. source

$ORMP +1.8% Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials. source

$SAVA +1.9% Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease. source

$AVIR +- 0.0% Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses. source

$IMCR +8.4% Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma. source

$UTHR -0.7% United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021. source

$TBPH -35.0% On 8/23 Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis. source

$CYTR +16.7% CytRx Highlights Orphazyme’s Published Results from its Phase 2/3 Trial of Arimoclomol in Niemann- Pick Disease Type C. source

Market update

$RFL -6.5% Rafael Holdings Announces Closing of $104.2 Million Private Placement source

$PROG +8.3% Progenity Announces Closing of $40 Million Underwritten Public Offering source


Posted by FS/JM



bottom of page